News
Why Viking Therapeutics stock reaction to obesity pill data is wildly ‘overdone’
Viking Therapeutics Inc (NASDAQ: VKTX) reported new clinical data for its oral obesity drug – sending shares sharply lower as investors balked at tolerability concerns and dropout rates. The Phase 2 trial showed promising weight loss results,
The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...
Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...
Viking Therapeutics stock plunges 37% as trial data sparks concerns over dropout rates and side effects despite weight loss ...
Viking Therapeutics Inc.’s worst stock drop in nine years has handed traders betting against the company a gain big enough to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback